Road Scholar | Transport Blog's

In a recent announcement, the FDA issued updates on exemptions from the Drug Supply Chain Security Act (DSCSA) final implementation deadline, extending compliance timelines for specific partners within the pharmaceutical industry.   This decision acknowledges the difficulties faced by some manufacturers and distributors in meeting the stringent traceability requirements, despite the Act being in place for over a decade.   The FDA aims to minimize potential disruptions in the pharmaceutical supply chain to ensure critical medications remain accessible to patients. Background of the DSCSA The DSCSA, enacted in November 2013, was established to enhance drug traceability within the U.S. pharmaceutical supply chain.   By mandating unit-level serialization and visibility from manufacturers to dispensers, the DSCSA addresses issues of counterfeiting, contamination, and drug shortages.   Under this law, each pharmaceutical product moving through the supply chain must be traceable back to

The report quantifies the direct and indirect losses stemming from detention times, totaling billions in lost productivity and additional costs.   Fleets are charging detention fees, yet fewer than half are paid, indicating a widespread acceptance of unpaid wait times.   Additionally, the report uncovers that detained trucks are driven faster post-detention, and drivers are also speeding on routes known for detainment. Financial Impacts of Driver Detention ATRI's research reveals staggering numbers: the for-hire trucking sector alone lost over 135 million hours to detention in 2023, translating to $3.6 billion in direct expenses.   Not only does this amount to unpaid labor for drivers, but it also incurs operational costs for fleets, particularly when unplanned delays push delivery schedules or require last-minute rerouting.   Although 94.5% of fleets impose detention fees, fewer than half of these invoices are paid, which poses a severe cash flow problem and leaves carriers co